 methotrex vinblastin doxorubicin cisplatin metastat breast cancer phase II trial hoosier oncolog group forty-six elig patient metastat breast cancer mbc combin methotrex vinblastin doxorubicin cisplatin m-vac first-lin chemotherapi patient evalu respons object respons complet respons median durat respons month rang month median surviv time entri month rang month myelosuppress common dose-limit toxic patient grade leukopenia granulocytopen fever septic death cumul grade anemia patient stomat patient activ toxic regimen first-lin therapi mbc m-vac respons rate surviv durat similar toxic combin regimen m-vac prefer combin chemotherapi clinic set